Last reviewed · How we verify

phosphate and betamethasone acetate, 2 mL.

Hospital Italiano de Buenos Aires · FDA-approved active Small molecule

phosphate and betamethasone acetate, 2 mL. is a Corticosteroid (glucocorticoid) Small molecule drug developed by Hospital Italiano de Buenos Aires. It is currently FDA-approved for Intra-articular injection for inflammatory arthritis and joint inflammation, Soft-tissue injection for bursitis, tendinitis, and localized inflammatory conditions, Dermatologic inflammatory conditions. Also known as: cronodose.

Betamethasone acetate is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.

Betamethasone acetate is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Intra-articular injection for inflammatory arthritis and joint inflammation, Soft-tissue injection for bursitis, tendinitis, and localized inflammatory conditions, Dermatologic inflammatory conditions.

At a glance

Generic namephosphate and betamethasone acetate, 2 mL.
Also known ascronodose
SponsorHospital Italiano de Buenos Aires
Drug classCorticosteroid (glucocorticoid)
TargetGlucocorticoid receptor (GR)
ModalitySmall molecule
Therapeutic areaImmunology / Rheumatology / Dermatology
PhaseFDA-approved

Mechanism of action

Betamethasone acetate is a synthetic glucocorticoid that enters cells and binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene expression. This results in decreased production of inflammatory mediators (cytokines, chemokines, adhesion molecules) and suppression of immune cell activation and migration. The phosphate salt formulation enhances solubility and allows for parenteral administration, typically as an intra-articular or soft-tissue injection.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about phosphate and betamethasone acetate, 2 mL.

What is phosphate and betamethasone acetate, 2 mL.?

phosphate and betamethasone acetate, 2 mL. is a Corticosteroid (glucocorticoid) drug developed by Hospital Italiano de Buenos Aires, indicated for Intra-articular injection for inflammatory arthritis and joint inflammation, Soft-tissue injection for bursitis, tendinitis, and localized inflammatory conditions, Dermatologic inflammatory conditions.

How does phosphate and betamethasone acetate, 2 mL. work?

Betamethasone acetate is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.

What is phosphate and betamethasone acetate, 2 mL. used for?

phosphate and betamethasone acetate, 2 mL. is indicated for Intra-articular injection for inflammatory arthritis and joint inflammation, Soft-tissue injection for bursitis, tendinitis, and localized inflammatory conditions, Dermatologic inflammatory conditions.

Who makes phosphate and betamethasone acetate, 2 mL.?

phosphate and betamethasone acetate, 2 mL. is developed and marketed by Hospital Italiano de Buenos Aires (see full Hospital Italiano de Buenos Aires pipeline at /company/hospital-italiano-de-buenos-aires).

Is phosphate and betamethasone acetate, 2 mL. also known as anything else?

phosphate and betamethasone acetate, 2 mL. is also known as cronodose.

What drug class is phosphate and betamethasone acetate, 2 mL. in?

phosphate and betamethasone acetate, 2 mL. belongs to the Corticosteroid (glucocorticoid) class. See all Corticosteroid (glucocorticoid) drugs at /class/corticosteroid-glucocorticoid.

What development phase is phosphate and betamethasone acetate, 2 mL. in?

phosphate and betamethasone acetate, 2 mL. is FDA-approved (marketed).

What are the side effects of phosphate and betamethasone acetate, 2 mL.?

Common side effects of phosphate and betamethasone acetate, 2 mL. include Local injection site reactions (pain, swelling, erythema), Transient hyperglycemia, Systemic corticosteroid effects with repeated or high-dose use (HPA axis suppression, immunosuppression), Infection risk at injection site.

What does phosphate and betamethasone acetate, 2 mL. target?

phosphate and betamethasone acetate, 2 mL. targets Glucocorticoid receptor (GR) and is a Corticosteroid (glucocorticoid).

Related